• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳香酶抑制剂诱导的乳腺密度变化:临床与遗传效应。

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

机构信息

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Med Inn Building C450, Ann Arbor, MI 48109-5843, USA.

出版信息

Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.

DOI:10.1038/bjc.2013.587
PMID:24084768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3817329/
Abstract

BACKGROUND

Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.

METHODS

Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.

RESULTS

Of the 503 enrolled subjects, 259 had both paired mammograms at baseline and following 24 months of treatment and evaluable DNA. We observed a statistically significant decrease in mean MPD from 17.1 to 15.1% (P<0.001), more pronounced in women with baseline MPD ≥20%. No AI-specific difference in change in MPD was identified. No significant associations between change in MPD and inherited genetic variants were observed.

CONCLUSION

Subjects with higher baseline MPD had a greater average decrease in MPD with AI therapy. There does not appear to be a substantial effect of inherited variants in biologically selected candidate genes.

摘要

背景

乳腺密度的变化可能预测接受乳腺癌辅助激素治疗的女性的结局。我们进行了一项前瞻性临床试验,以评估参与雌激素代谢和信号转导的基因中的遗传变异对芳香酶抑制剂(AI)治疗期间乳腺 X 线摄影百分比密度(MPD)变化的影响。

方法

入组了正在接受辅助 AI 治疗的绝经后乳腺癌女性,她们参加了一项多中心、随机临床试验,比较依西美坦与来曲唑,旨在鉴定 AI 诱导的 MPD 变化与候选基因中单核苷酸多态性之间的相关性。在治疗 24 个月前后对受试者进行单侧头尾位乳腺 X 线摄影。

结果

在入组的 503 名受试者中,有 259 名受试者在基线和 24 个月治疗后都有双侧乳腺 X 线摄影且可评估 DNA。我们观察到 MPD 的平均从 17.1%下降到 15.1%(P<0.001),基线 MPD≥20%的女性更明显。在 MPD 变化方面,未发现 AI 特异性差异。未观察到 MPD 变化与遗传变异之间存在显著关联。

结论

基线 MPD 较高的受试者接受 AI 治疗后 MPD 平均下降幅度更大。在生物学选择的候选基因中,遗传变异似乎没有明显的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/364d/3817329/b74a9d980c9d/bjc2013587f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/364d/3817329/2428ecad6b70/bjc2013587f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/364d/3817329/b74a9d980c9d/bjc2013587f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/364d/3817329/2428ecad6b70/bjc2013587f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/364d/3817329/b74a9d980c9d/bjc2013587f2.jpg

相似文献

1
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.芳香酶抑制剂诱导的乳腺密度变化:临床与遗传效应。
Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.
2
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.基因变异与来曲唑和依西美坦对骨量及骨转换的影响之间的关联。
Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.
3
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.早期乳腺癌女性辅助依西美坦与阿那曲唑对骨密度的影响(MA.27B):一项随机对照试验的伴随分析。
Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11.
4
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.降低绝经后女性他莫昔芬治疗结束后乳腺癌复发风险。
Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013.
5
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.早期乳腺癌因治疗中出现的症状而导致芳香化酶抑制剂停药的预测因素。
J Clin Oncol. 2012 Mar 20;30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13.
6
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.绝经后接受辅助阿那曲唑治疗的女性的乳腺密度和循环雌激素变化。
Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.
7
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.与依西美坦相比,来曲唑在新辅助乳腺癌治疗中能更有效地抑制血清雌激素。
Breast Cancer Res Treat. 2024 Jul;206(2):347-358. doi: 10.1007/s10549-024-07313-x. Epub 2024 Apr 23.
8
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.绝经后早期乳腺癌患者接受来曲唑治疗后,血浆雌酮硫酸酯浓度与 CYP19A1 基因位点的遗传变异。
Breast Cancer Res Treat. 2013 Jan;137(1):167-74. doi: 10.1007/s10549-012-2306-z. Epub 2012 Nov 6.
9
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.芳香化酶抑制剂在绝经后乳腺癌女性辅助治疗中的获益。
MedGenMed. 2005 Aug 24;7(3):20.
10
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.患者报告的症状及辅助性芳香化酶抑制剂治疗的中断
Cancer. 2014 Aug 15;120(16):2403-11. doi: 10.1002/cncr.28756. Epub 2014 May 6.

引用本文的文献

1
Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review.乳腺密度作为乳腺癌风险因素的遗传结构:系统综述。
Clin Transl Oncol. 2023 Jun;25(6):1729-1747. doi: 10.1007/s12094-022-03071-8. Epub 2023 Jan 13.
2
Association Between Lifestyle Changes, Mammographic Breast Density, and Breast Cancer.生活方式改变与乳腺密度和乳腺癌的关系。
Oncologist. 2022 Jul 5;27(7):548-554. doi: 10.1093/oncolo/oyac084.
3
Biological Mechanisms and Therapeutic Opportunities in Mammographic Density and Breast Cancer Risk.

本文引用的文献

1
Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.乳腺 X 线摄影密度降低是绝经后乳腺癌患者接受辅助他莫昔芬治疗反应的预后标志物。
J Clin Oncol. 2013 Jun 20;31(18):2249-56. doi: 10.1200/JCO.2012.44.5015. Epub 2013 Apr 22.
2
Mammographic breast density response to aromatase inhibition.乳腺密度对芳香酶抑制的反应。
Clin Cancer Res. 2013 Apr 15;19(8):2144-53. doi: 10.1158/1078-0432.CCR-12-2789. Epub 2013 Mar 6.
3
Polymorphisms in hormone metabolism and growth factor genes and mammographic density in Norwegian postmenopausal hormone therapy users and non-users.
乳腺X线密度与乳腺癌风险的生物学机制及治疗机遇
Cancers (Basel). 2021 Oct 27;13(21):5391. doi: 10.3390/cancers13215391.
4
Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.识别具有乳腺癌风险增加的女性,并实施降低风险策略和补充性影像学检查。
Breast Cancer. 2022 Jan;29(1):19-29. doi: 10.1007/s12282-021-01298-x. Epub 2021 Oct 19.
5
Genetic Influences in Breast Cancer Drug Resistance.乳腺癌耐药中的遗传影响
Breast Cancer (Dove Med Press). 2021 Feb 9;13:59-85. doi: 10.2147/BCTT.S284453. eCollection 2021.
6
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.绝经后乳腺癌患者的芳香化酶抑制剂血浆浓度变化与循环雌激素浓度无相关性。
Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.
7
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.前瞻性评估接受辅助芳香化酶抑制剂治疗的患者出现毒性反应时的患者报告结局和雌二醇及药物浓度。
Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.
8
Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors.他莫昔芬和芳香化酶抑制剂对乳腺体积密度的纵向影响
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):930-937. doi: 10.1158/1055-9965.EPI-16-0882. Epub 2017 Feb 1.
9
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.依西美坦和来曲唑治疗对绝经后乳腺癌女性血浆雌激素浓度的影响:一项随机试验
Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.
10
Relationship Between Breast Density and Selective Estrogen-Receptor Modulators, Aromatase Inhibitors, Physical Activity, and Diet: A Systematic Review.乳腺密度与选择性雌激素受体调节剂、芳香化酶抑制剂、身体活动及饮食之间的关系:一项系统评价
Integr Cancer Ther. 2016 Jun;15(2):127-44. doi: 10.1177/1534735416628343. Epub 2016 Apr 29.
挪威绝经后激素治疗使用者和非使用者中激素代谢和生长因子基因多态性与乳房X线密度的关系
Breast Cancer Res. 2012 Oct 27;14(5):R135. doi: 10.1186/bcr3337.
4
The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors.乳腺钼靶密度和循环性激素水平的遗传性:两个独立的乳腺癌风险因素。
Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2167-75. doi: 10.1158/1055-9965.EPI-12-0789. Epub 2012 Oct 16.
5
Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.乳腺密度变化作为激素受体阳性乳腺癌辅助内分泌治疗反应的预测替代指标。
Breast Cancer Res. 2012 Jul 6;14(4):R102. doi: 10.1186/bcr3221.
6
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.早期乳腺癌因治疗中出现的症状而导致芳香化酶抑制剂停药的预测因素。
J Clin Oncol. 2012 Mar 20;30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13.
7
A genome-wide linkage study of mammographic density, a risk factor for breast cancer.全基因组连锁研究乳腺密度,乳腺癌的一个风险因素。
Breast Cancer Res. 2011;13(6):R132. doi: 10.1186/bcr3078. Epub 2011 Dec 21.
8
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.绝经后乳腺癌女性的血浆来曲唑浓度与 CYP2A6 基因变异、体重指数和年龄相关。
Clin Pharmacol Ther. 2011 Nov;90(5):693-700. doi: 10.1038/clpt.2011.174. Epub 2011 Oct 5.
9
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.绝经后接受辅助阿那曲唑治疗的女性的乳腺密度和循环雌激素变化。
Cancer Prev Res (Phila). 2011 Dec;4(12):1993-2001. doi: 10.1158/1940-6207.CAPR-11-0154. Epub 2011 Sep 1.
10
Exemestane for breast-cancer prevention in postmenopausal women.依西美坦用于绝经后妇女的乳腺癌预防。
N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4.